Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

304.21USD
2 Sep 2015
Change (% chg)

$11.71 (+4.00%)
Prev Close
$292.50
Open
$298.48
Day's High
$304.42
Day's Low
$293.98
Volume
644,150
Avg. Vol
747,216
52-wk High
$480.13
52-wk Low
$265.55

BIIB.OQ

Chart for BIIB.OQ

About

Biogen Inc., formerly Biogen Idec Inc., is a global biopharmaceutical company. The Company is focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. The Company develops, manufactures and markets products designed for the treatment of multiple sclerosis... (more)

Overall

Beta: 1.01
Market Cap(Mil.): $68,787.00
Shares Outstanding(Mil.): 235.17
Dividend: --
Yield (%): --

Financials

  BIIB.OQ Industry Sector
P/E (TTM): 19.79 35.72 35.82
EPS (TTM): 14.78 -- --
ROI: 27.74 15.55 15.00
ROE: 31.54 16.11 15.86
Search Stocks

Biogen patent survives challenge by hedge fund manager Bass

- In another setback for prominent hedge fund manager Kyle Bass and his campaign to eliminate some drug patents, the U.S. Patent and Trademark Office on Wednesday declined to hold a trial on the validity of a patent on Biogen Inc's multiple sclerosis drug Tecfidera.

02 Sep 2015

Biogen patent survives challenge by hedge fund manager Bass

NEW YORK - In another setback for prominent hedge fund manager Kyle Bass and his campaign to eliminate some drug patents, the U.S. Patent and Trademark Office on Wednesday declined to hold a trial on the validity of a patent on Biogen Inc's multiple sclerosis drug Tecfidera.

02 Sep 2015

Biogen patent survives challenge by hedge fund manager Kyle Bass

NEW YORK, Sept 2 - In another setback for prominent hedge fund manager Kyle Bass and his campaign to eliminate some drug patents, the U.S. Patent and Trademark Office on Wednesday declined to hold a trial on the validity of a patent on Biogen Inc's multiple sclerosis drug Tecfidera.

02 Sep 2015

UPDATE 1-CVS strips Viagra, other top drugs, from insurance coverage

Aug 5 - CVS Health Corp, which operates the nation's second-biggest pharmacy benefit manager, said that next year it will exclude an additional 31 prescription medicines from insurance coverage, including Viagra and widely used treatments for diabetes and multiple sclerosis.

05 Aug 2015

CVS strips Viagra, other top drugs, from insurance coverage

Aug 5 - CVS Health Corp, which operates the nation's second-biggest pharmacy benefit manager, said that next year it will exclude an additional 31 prescription medicines from insurance coverage, including Viagra and widely used treatments for diabetes and multiple sclerosis.

05 Aug 2015

US STOCKS-Wall St slides to end rough week on macro, earnings concerns

* Indexes down: Dow 0.9 pct, S&P 1.1 pct, Nasdaq 1.1 pct (Updates to close)

24 Jul 2015

Biogen halves sales growth forecast as Tecfidera demand stalls

- Biogen Inc more than halved its sales growth forecast for 2015, saying it expects demand for its flagship multiple sclerosis (MS) drug, Tecfidera, to continue slowing this year in the United States.

24 Jul 2015

UPDATE 3-Biogen halves sales growth forecast as Tecfidera demand stalls

* Shares fall as much as 18.8 percent (Recasts, analyst and executive comment, shares)

24 Jul 2015

US STOCKS-Wall Street lower amid mixed earnings, fall in commodities

* Amazon jumps to record high after posting unexpected profit

24 Jul 2015

Biogen profit rises 30 pct on higher Tecfidera sales

July 24 - Biogen Inc reported a 30 percent rise in quarterly profit, driven by strong sales of its top-selling oral multiple sclerosis drug, Tecfidera.

24 Jul 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : New Constructs, LLC
$25.00
Provider : Wright Reports
$75.00
Provider : ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks